Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission

Autor: Pierre‐Yves Dumas, Emilie Bérard, Claire Bréal, Stéphanie Dulucq, Delphine Réa, Franck Nicolini, Edouard Forcade, Melody Dufossée, Jean‐Max Pasquet, Béatrice Turcq, Audrey Bidet, Noel Milpied, Julie Déchanet‐Merville, Xavier Lafarge, Gabriel Etienne, François‐Xavier Mahon, French Intergroup in Chronic Myeloid Leukemia
Přispěvatelé: Service d’Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, CHU Bordeaux [Bordeaux], Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY (Equipe 5 - EQUITY), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Service d'Hématologie Clinique et Thérapie Cellulaire [CHU Bordeaux], Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux], Dpt hématologie [CHU Bordeaux], Service d’Hématologie, Hôpital Saint Louis, Paris, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), ImmunoConcEpT, UMR 5164, Bordeaux, Centre National de la Recherche Scientifique (CNRS), Actions for OnCogenesis understanding and Target Identification in ONcology (ACTION), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER-Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Turcq, Beatrice, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunology from Concept and Experiments to Translation (ImmunoConcept), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology
Male
Cancer Research
[SDV]Life Sciences [q-bio]
0302 clinical medicine
Receptors
KIR
Genotype
Cytotoxic T cell
Medicine
Receptor
Original Research
Innate lymphoid cell
Remission Induction
Myeloid leukemia
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
treatment‐free remission
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
3. Good health
[SDV] Life Sciences [q-bio]
Killer Cells
Natural
Receptors
KIR2DL5
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Imatinib Mesylate
[SDV.IMM]Life Sciences [q-bio]/Immunology
Female
Tyrosine kinase
medicine.drug
[SDV.IMM] Life Sciences [q-bio]/Immunology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Antineoplastic Agents
lcsh:RC254-282
Immunophenotyping
03 medical and health sciences
[SDV.CAN] Life Sciences [q-bio]/Cancer
chronic myeloid leukemia
Leukemia
Myelogenous
Chronic
BCR-ABL Positive
[SDV.BBM] Life Sciences [q-bio]/Biochemistry
Molecular Biology
Humans
Radiology
Nuclear Medicine and imaging
[SDV.BBM]Life Sciences [q-bio]/Biochemistry
Molecular Biology
killer immunoglobulin‐like receptors
Protein Kinase Inhibitors
Aged
business.industry
Clinical Cancer Research
Genetic Variation
Imatinib
natural killer
Discontinuation
030104 developmental biology
imatinib
Haplotypes
Withholding Treatment
Cancer research
business
Biomarkers
Zdroj: Cancer Medicine
Cancer Medicine, Wiley, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
Cancer Medicine, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
Cancer Medicine, Vol 8, Iss 11, Pp 4976-4985 (2019)
ISSN: 2045-7634
Popis: International audience; Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various receptors. Killer immunoglobulin‐like receptors (KIR) belong to these receptors and are involved in maturation process, then in the activation abilities of NK cells. Methods: We investigated the prognostic impact of the KIR2DL5B genotype in 240 CML patients included in two clinical trials investigating tyrosine kinase inhibitors (TKI) discontinuation: STIM and STIM2. Results: After adjustment for standard risk factors in CML, we found that the inhibitory receptor KIR2DL5B‐positive genotype was independently related to a delayed second deep molecular remission (HR 0.54, 95% CI [0.32‐0.91], P = 0.02) after TKI rechallenge but not to time to first deep molecular remission or treatment‐free remission rates. Conclusion: These results suggest that KIR2DL5B could carry a role in lymphocyte‐mediated control of leukemic residual disease control in patient with CML relapse.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje